Donald Bellgrau
Founder at ApopLogic Pharmaceuticals, Inc.
Donald Bellgrau active positions
| Companies | Position | Start | End |
|---|---|---|---|
| The University of Colorado | Corporate Officer/Principal | 2009-09-13 | - |
ApopLogic Pharmaceuticals, Inc.
 ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Director/Board Member | 2005-12-31 | - |
| Founder | 2005-12-31 | - |
Career history of Donald Bellgrau
Former positions of Donald Bellgrau
| Companies | Position | Start | End |
|---|---|---|---|
| GLOBEIMMUNE, INC. | Founder | 1995-02-09 | - |
| Basel Institute for Immunology | Corporate Officer/Principal | - | - |
Training of Donald Bellgrau
| University of Pennsylvania | Doctorate Degree |
Statistics
International
| United States | 5 |
| Switzerland | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Founder | 2 |
| Doctorate Degree | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GLOBEIMMUNE, INC. | Health Technology |
| Private companies | 1 |
|---|---|
ApopLogic Pharmaceuticals, Inc.
ApopLogic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ApopLogic Pharmaceuticals, Inc. researches and develops pharmaceutical products. It focuses on the development and commercialization of B201, is a rationally-designed synthetic peptide dimer of a potent decapeptide bradykinin B1&B2 receptor antagonist that directly induces apoptosis of cancer cells that overexpress these receptors and AP-300 is used in the neo-adjuvant or adjuvant setting with standard-of-care agents to improve survival outcomes in humans and companion animals with any accessible solid tumor including carcinomas, sarcomas and lymphomas. The company was founded in 2006 by Richard C. Duke, Donald Bellgrau, Paul A. Bunn, Daniel Chan, Lajos Gera, Jaime F. Modiano and John M. Stewart and is headquartered in Aurora, CO. | Health Technology |
- Stock Market
- Insiders
- Donald Bellgrau
- Experience
